Baird Maintains a 'Neutral' on Amylin Pharmaceuticals (AMLN); Q3-11: Continued Revenue Stabilization and a New Indication for Byetta

Baird maintains a 'Neutral' on Amylin Pharmaceuticals (NASDAQ: AMLN).

Baird analyst says, "AMLN continues to conservatively manage expenses and has successfully stabilized revenues through price increases. Earnings matter little now, but the expected Q1-12 approval of Bydureon will bring focus back to the commercialization story. Consensus Bydureon expectations have come down notably, creating a situation contrarian investors might want to monitor, but significant franchise growth is still needed to drive AMLN through to profitability, and we still need more conviction there...Our 2011E and 2012E EPS change only slightly to ($0.76) and ($0.60), respectively, on revenue fine-tuning."

For more ratings news on Amylin Pharmaceuticals click here and for the rating history of Amylin Pharmaceuticals click here.

Shares of Amylin Pharmaceuticals closed at $10.24 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery